Pluristem Therapeutic Inc. (NasdaqCM: PSTI) is a bio-therapeutics company dedicated to the commercialization of allogeneic (non-personalized) cell therapy products derived from the human placenta, an organ that has traditionally been considered medical waste after childbirth. The company uses its PLX products for the treatment of a variety of ischemic and autoimmune disorders where current therapies are unavailable or inadequate. Pluristem's adherent stromal cells are and a non-embryonic, non-controversial source of cells.
Link to this comment:
All Comments (0)